Adaptimmune Therapeutics PLC
ADAPY · Biological Products, (No Disgnostic Substances)
Latest available SEC filing: SCHEDULE 13G/A ·
Latest disclosures
-
Form SCHEDULE 13G/A
SEC filing · Filed
-
Hill Christopher James: Form 3
Insider disclosure · Filed · Report period 10 Sep 2025
-
Form 3
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Latest financial period: Q2 2025
Financial facts · Filed
-
Form 10-Q
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- ADAPY · 00653A107 - American Depositary Shares, each representing 6 Ordinary Shares
Company details and SEC sources
CIK 0001621227 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- ADAPY on OTC
- SEC industry group
- Biological Products, (No Disgnostic Substances) (Office of Life Sciences)
- Business address
- 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire
- Incorporated in
- United Kingdom
- Fiscal year end
- 31 December
- Former names on EDGAR
- Adaptimmune Ltd (to 17 Mar 2015)
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields